Relmada Therapeutics Inc. is scratching its collective chin as it sifts through data from the failed phase III Reliance III study of REL-1017 (esmethadone) in treating major depressive disorder (MDD). A higher-than-expected placebo response, however, prompted the company to label the study’s results as “paradoxical.” Read More
A phase IIb trial of nangibotide in septic shock has demonstrated preliminary signs of efficacy in a subset of biomarker-defined patients and provided its developer, Inotrem SA, with a dataset that will inform the design of a registration program for the drug. Subject to agreement from regulatory agencies, the company aims to move the triggering receptor on myeloid cells 1 inhibitor into a first phase III trial in early 2024. “We should have a clearer picture by the beginning of the second next year,” CEO Sven Zimmermann told BioWorld. Read More
Odyssey Therapeutics Inc. closed a hefty $168 million series B round to progress multiple small-molecule and protein-based drug discovery and development programs in autoimmune disease and cancer. Read More
Biopharma deals lost speed in the third quarter and are now falling behind each of the last two years, while merger and acquisition values doubled the amount from the first half of 2022. The industry completed a total of 283 deals, including licensings, collaborations and joint ventures, in Q3. They were worth a combined value of $40.98 billion, a rise of 8.3% over the second quarter but down by 28.7% from the first quarter. Read More
GSK plc has announced results from its respiratory syncytial virus (RSV) vaccine in older people that look stronger than those from its rival, Pfizer Inc., as the race to develop a first ever vaccine against the common respiratory disease heats up. Read More
Nanjing Iaso Biotherapeutics Co. Ltd. has out-licensed a fully human anti-CD19 binder to Cabaletta Bio Inc. in a deal worth up to $162 million. Read More
Prescription drug names are generally invented words that are often easier to spell than they are to pronounce. And, for the most part, they’re meaningless until they’ve been associated with a drug. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Adept, Aytu, Enterin, Genuv, GPCR, Jacobio, Merck KGaA. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aim, Biomind, Eagle, Elevar, Galectin, Merck & Co., Moerna, Pfizer, Regeneron, Sisaf. Read More
